Johnson & Johnson Family of Companies
NEWS
As the Democratic-led House of Representatives begin to file a number of bills aimed at lowering the cost of prescription drugs in the United States, Johnson & Johnson has joined the ranks of pharma companies that started out the new year with a price hike.
With the JP Morgan Healthcare Conference ending today, it’s worth noting the word “healthcare” in the title, not “biopharma.” It’s not as if the biotech and pharmaceutical industry isn’t part of healthcare, but BioSpace’s reporting focuses on biopharma. Here’s a look at some of the more healthcare-oriented stories coming out of San Francisco this week.
Ahead of the JP Morgan Healthcare Conference, Jamie Dimon, chief executive officer of JP Morgan Chase, hosted a private dinner for biopharma executives Sunday night. Although the dinner was private, apparently one of the hot topics of discussion was a company not represented at the party—Amazon.
Federal corporate tax cuts that were framed as a way to give a boost to employment across the United States have been more beneficial to companies and shareholders than the average worker or consumer, a new report issued by the advocacy group Americans for Tax Fairness shows.
With the holidays over and the JP Morgan Healthcare Conference next week, companies were clearly revving their engines, ready to race into the new year. Here’s a roundup of some of the top deals that were announced today.
Under the terms of the deal, Janssen is paying Locus $20 million up front. Locus will be eligible for up to a total of $798 million in development and commercial milestones, as well as royalties on any product sales.
PwC recently came out with the latest version of their annual R&D spending report, and while there is a lot of interesting information to digest in this report, there are a few companies in particular that stand out within the field of biotechnology.
As news continues about Johnson & Johnson’s talcum powder containing carcinogenic asbestos, more than 100 drug inspectors in India are seizing samples, characterized The Times of India. The company, however, downplays that description, suggesting that the samples are fairly routine.
A Reuters analysis of company documents reveals that Johnson & Johnson knew about levels of asbestos contamination in its talc products, but did not report it to the FDA.
JOBS
IN THE PRESS